Similar articles

• Lanadelumab (Takhzyro) for prevention of hereditary angioedema.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Mar 8;63(1619):e41-e42. Med Lett Drugs Ther. 2021. PMID: 33755657 Review. No abstract available.
• A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.

  Gao Y, Hwang J, Hwang G, Craig T. Gao Y, et al. Drugs Today (Barc). 2022 Feb;58(2):59-67. doi: 10.1358/dot.2022.58.2.3369191. Drugs Today (Barc). 2022. PMID: 35188140 Review.
• Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.

  Powell J, Piszczatoski C, Rubido E. Powell J, et al. Ann Pharmacother. 2022 Apr;56(4):488-493. doi: 10.1177/10600280211032982. Epub 2021 Jul 20. Ann Pharmacother. 2022. PMID: 34282650 Review.
• A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

  Hwang G, Johri A, Ng S, Craig T. Hwang G, et al. Immunotherapy. 2019 Aug;11(11):937-944. doi: 10.2217/imt-2018-0197. Epub 2019 Jun 25. Immunotherapy. 2019. PMID: 31234673 Review.
• Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.

  Manning ME, Kashkin JM. Manning ME, et al. Allergy Asthma Proc. 2021 Jul 14;42(4):274-282. doi: 10.2500/aap.2021.42.210034. Epub 2021 Jun 14. Allergy Asthma Proc. 2021. PMID: 34127176 Review.